organ revenu growth ta ds
acceler csm stabil
sale estim adj ep beat street
revenu y/i cc rel recast
our/th street driven technolog analyt
ta ds segment adj ebitda y/i
margin our/th street est adj ep y/i
in-lin estimate street first look note link
ta ds acceler csm stabil
impress end ta organ revenu growth
acceler histor averag help double-digit growth
real-world evid rwe recent acquisit annual
contribut organ revenu ds continu strong win streak net
book-to-bil quarter grew organ show earli sign revenu
acceler addit seem like big pharma increasingli buy iqv next-
gener data technology-driven clinic drug develop solut larg
pharma book repres major iqv book grew
repres smart trial book quarter sinc merger
last least contract sale medic solut csm segment declin
organ low double-digit declin seen manag
see posit sign stabil csm in-lin channel check
note earn preview guid organ revenu growth
overal encourag iqv recent high win rate increasingli
reflect organ revenu growth rate reiter buy rate
rais estim po
increas est reflect beat higher-than-expect guidanc
model revenu y/i organ fx
adj ep y/i model
revenu y/i organ fx
adj ep y/i rais po base
adj ep estimate
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
ia lead global provid
inform technolog solut contract
research servic compani world
largest cro contract research organ
largest sourc drug util data
focus use data advanc analyt
scienc help healthcar stakehold find better
solut patient compani
employe serv client
posit pharma biotech end
market remain healthi addit also
believ abl grow competit
leverag differenti next-gener
clinic develop offer commerci
technolog solut potenti growth
upsid capit deploy
price object base adj ep estim multipl
line histor averag think warrant posit
current cro industri trend risk price object lower biopharma
commerci spend custom consolid data suppli secur risk competit
technolog risk execut risk regulatori risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
